Active, Not Recruiting
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462
- Conditions
- Autoimmune Diseases, Chronic Disease, Disease Attributes, +15 more
- Locations
-
- AZ Kidney Dise and Hypertension Ctr Glendale, Arizona, United States
- Kaiser Permanente San Diego, California, United States
- North America Research Institute San Dimas, California, United States
- University of Colorado Anschutz Aurora, Colorado, United States